14.79
-0.06 (-0.40%)
| Previous Close | 14.85 |
| Open | 14.49 |
| Volume | 1,100,454 |
| Avg. Volume (3M) | 1,546,106 |
| Market Cap | 1,949,921,920 |
| Price / Earnings (TTM) | 26.41 |
| Price / Earnings (Forward) | 19.57 |
| Price / Sales | 7.91 |
| Price / Book | 5.35 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 16.11% |
| Operating Margin (TTM) | 37.43% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 24.20% |
| Total Debt/Equity (MRQ) | 22.25% |
| Current Ratio (MRQ) | 5.93 |
| Operating Cash Flow (TTM) | 64.29 M |
| Levered Free Cash Flow (TTM) | 47.49 M |
| Return on Assets (TTM) | 5.20% |
| Return on Equity (TTM) | 11.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Aurinia Pharmaceuticals Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.88 |
|
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 9.07% |
| % Held by Institutions | 47.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (Jefferies, 41.99%) | Buy |
| Median | 16.00 (8.18%) | |
| Low | 15.00 (RBC Capital, 1.42%) | Hold |
| Average | 17.33 (17.17%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 14.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 03 Dec 2025 | 16.00 (8.18%) | Hold | 14.91 |
| Jefferies | 07 Nov 2025 | 21.00 (41.99%) | Buy | 14.61 |
| RBC Capital | 05 Nov 2025 | 15.00 (1.42%) | Hold | 14.45 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |